From whole cell to acellular pertussis vaccines

Reviews and Research in Medical Microbiology

Volumn 7, Issue 1, 1996, Pages 13-21

  Willems, Rob J L ^a   Mooi, Frits R ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Adverse reactions; B. parapertussis; Bordetella pertussis; Whooping cough vaccine

Indexed keywords

PERTUSSIS VACCINE;

BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; PERTUSSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VACCINATION;

EID: 0030024386     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-199601000-00002     Document Type: Review

References (62)

1. Fine PE, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987; 9: 866-883.
2. Porter JF, Conner K, Donachie W. Isolation and characterization of Bordetella parapertussis-like bacteria from ovine lungs. Microbiology 1994; 140: 255-261.
3. Musser JM, Hewlett EL, Peppler MS, Selander RK. Genetic diversity and relationships in populations of Bordetella spp. J Bacteriol 1986; 166: 230-237.
4. Mooi FR. Genes for the filamentous hemagglutinin and fimbriae of Bordetella pertussis: colocation, coregulation, and cooperation? In: Miller VL, Kaper JB, Portnoy DA, Isberg RR, eds. Molecular genetics of bacterial pathogenesis. Washington: American Society for Microbiology, 1994.
5. Lee CK, Roberts AL, Finn TM, Knapp S, Mekalanos JJ. A new assay for invasion of HeLa 229 cells by Bordetella pertussis: effects of inhibitors, phenotypic modulation, and genetic alterations. Infect Immun 1990; 58: 2516-2522.
6. Leininger E, Ewanowich CA, Bhargava A, Peppler MS, Kenimer JG, Brennan MJ. Comparative roles of the Arg-Gly-Asp sequence present in the Bordetella pertussis adhesins pertactin and filamentous hemagglutinin. Infect Immun 1992; 60: 2380-2385.
7. Kendrick PL, Eldering G, Dixon MK, Misner J. Mouse protection tests in the study of pertussis vaccines: a comparative series using intracerebral route of challenge. Am J Public Health 1947; 37: 803-810.
8. Medical Research Council. Vaccination against whooping-cough: Relation between protection in children and results of laboratory tests. Br Med J 1956; 2: 454-462.
9. Moxon ER, Rappuoli R. Modern vaccines; Haemophilus influenzae infections and whooping cough. Lancet 1990; 335: 1324-1329.
10. Poolman JT, Hamstra HJ, Barlow AK, Kuipers B, Loggen H, Nagel J. Outer membrane vesicles of Bordetella pertussis are protective antigens in the mouse intracerebral challenge model. In: Manclark CR, ed. Proceedings of the Sixth International Symposium on Pertussis. 1990: 202-206.
11. He Q, Viljanen MK, Ölander RM, Bogaerts H, De Grave D, Ruuskanen O, Mertsola J. Antibodies to filamentous hemagglutinin of Bordetella pertussis and protection against whooping cough in schoolchildren. J Infect Dis 1994; 170: 705-708.
12. Medical Research Council. Vaccination against whooping cough: Final report. Br Med J 1959; 1: 994-1000.
13. Mink CM, O'Brien CH, Wassilak S, Deforest A, Meade BD. Isotype and antigen specificity of pertussis agglutinins following whole-cell pertussis vaccination and infection with Bordetella pertussis. Infect Immun 1994; 62: 1118-1120.
14. Huovila R, Kuronen T, Jannes L, Hallman N. Agglutinins in children vaccinated with the DTP vaccines used in Finland, serotypes of Bordetella pertussis strains isolated during whooping cough epidemics in 1976-1977 and whooping cough attack rate in children in the epidemic areas. Acta Pediatr Scand 1982; 298 (suppl): 21-25.
15. Preston NW, Carter EJ. Serotype specificity of vaccine-induced immunity to pertussis. Communicable Disease Report 1992; 2: 155-156.
16. Fine PE, Clarkson, JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987; 9: 866-883.
17. Miller E, Farrington CP. The current epidemiology of pertussis in the developed world: UK and West Germany. Tokai J Exp Clin Med 1988; 13: 97-101.
18. Farizo KM, Cochi SL, Zell ER, Brink EW, Wassilak SG, Patriarca PA. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis 1992; 14: 708-719.
19. Cromer BA, Goydos J, Hackell J, Mezzatesta J, Dekker C, Mortimer EA. Unrecognized pertussis infection in adolescents. Am J Dis Child 1993; 147: 575-577.
20. He Q, Viljanen MK, Nikkari S, Lyytakäinen R, Mertsola J. Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis 1994: 170: 873-877.
21. Grenfell BT, Anderson RM. Pertussis in England and Wales: an investigation of tranmission dynamics and control by mass vaccination. Proc Roy Soc Lond B Biol Sc 1989; 236: 213-252.
22. Mooi FR. Bordetella pertussis fimbriae. In: Klemm P, ed. Fimbriae - adhesion, genetics, biogenesis and vaccines. Boca Raton: CRC Press, 1994, pp. 115-125.
23. Goodman YE, Wort AJ, Jackson FL. Enzyme linked immunosorbent assay for detection of pertussis immunoglobulin A in nasopharyngeal secretions as an indicator of recent infection. J Clin Microbiol 1981; 13: 286-292.
24. Mink CA, Sirota NM, Nugent S. Outbreak of pertussis in a fully immunized adolescent and adult population. Arch Pediatr Adolesc Med 1994; 148: 153-157.
25. Aoyama T, Takeuchi Y, Goto A, Iwai H, Murase Y, Iwata T. Pertussis in adults. Am J Dis Child 1992; 146: 163-166.
26. Mink CM, Cherry JD, Christenson P, Lewis K, Pineda E, Shlian D, Dawson JA, Blumberg DASO. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992; 14: 464-471.
27. Neimark FM, Lugovaya LV, Belova ND. Bordetella parapertussis and its significance in the disease of pertussis. J Microbiol Epidem Immunobiol 1961; 32: 49-53.
28. Taranger J, Trollfors B, Lagergård T, Zackrisson G. Parapertussis infection followed by pertussis infection. Lancet 1994; 344: 1703.
29. Lautrop H. Epidemics of parapertussis. 20 years' observations in Denmark. Lancet 1971; i: 1195-1198.
30. Mortimer Jr EA. Pertussis vaccine. In: Plotkin SA, Mortimer Jr EA, eds. Vaccines. Philadelphia: WB Saunders, 1994, pp. 91-137.
31. Aoyama T, Murase Y, Gonda T, Iwata T. Type-specific efficacy of acellular pertussis vaccine. AJDC 1988; 142: 40-42.
32. Kimura M, and Kuno-Sakai, H. Developments in pertussis immunization in Japan. Lancet 1990; 336: 30-32.
33. Aoyama T, Iwata T, Iwai H, Murase Y, Saito T, Akamatsu T. Efficacy of acellular pertussis vaccine in young infants. J Infect Dis 1993; 167: 483-486.
34. Pittman M. The concept of pertussis as a toxin-mediated disease. Pediatr Infect Dis 1984; 3: 467-486.
35. Guiso N, Szatanik M, Rocancourt M. Protective activity of Bordetella adenylate cyclase hemolysin against bacterial colonization. Microb Pathog 1991; 11: 423-431.
36. Robbins JB, Pittman M, Trollfors B, Lagergard TA, Taranger J, Schneerson R. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr Infect Dis J 1993; 12: 795-807.
37. Heininger U, Stehr K, Schmitt-Grohe S, Lorenz C, Rost R, Christenson PD, Uberall M, Cherry JD. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J 1994; 13: 306-309.
38. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo controlled trial of two acellular pertussis vaccines in Sweden: Protective efficacy and adverse events. Lancet 1988; i: 955-960.
39. Storsaeter J, Hallander HO, Farrington CP, Olin P, Mölby R, Miller E. Secondary analysis of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990; 8: 457-461.
40. Chen RT, Broome CV, Weinstein RA, Weaver R, Tsai TF. Diphtheria in the United States 1971-1981. Am J Publ Health 1985; 75: 1393-1397.
41. Borska K, Simkovicova M. Studies on the circulation of Bordetella pertussis and Bordetella parapertussis in populations of children. J Hyg Epid Microbiol Immunol 1972; 16: 159-172.
42. Flosdorf EW, Bondi A, Felton H, McGuinness AC. Studies with Haemophilus pertussis: X. Comparative antigenic analysis of Bacillus parapertussis and Haemophilus pertussis, Phase I, with consideration of clinical significance. J Pediatr 1942; 21: 625-634.
43. Khelef N, Danve B, Quentin-Millet MJ, Guiso N. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species. Infect Immun 1993; 61: 486-490.
44. Li LJ, Dougan G, Novotny P, Charles IG P.70 pertactin, an outer membrane protein from Bordetella parapertussis: cloning, nucleotide sequence and surface expression in Escherichia coli. Mol Microbiol 1991; 5: 409-417.
45. Arico B, Rappuoli R. Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes. J. Bacteriol 1987; 169: 2847-2853.
46. Van der Zee A, Agterberg C, Peters M. Schellekens J. Mooi, FR. Polymerase chain reaction assay for pertussis: simultaneous detection and discrimination of Bordetella pertussis and Bordetella parapertussis. J Clin Microbiol 1993; 31: 2134-2140.
47. Anderson EL, Mink CM, Berlin BS, Shih CN, Tung FF, Belshe RB. Acellular pertussis vaccines in infants: evaluation of single component and two component products. Vaccine 1994; 12: 28-31.
48. Halperin SA, Barreto L, Friesen B, Meekison W. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children. Arch Pediatr Adolesc Med 1994; 148: 495-502.
49. Podda A, Carapella de Luca E, Contu B et al. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. J Pediatr 1994; 124: 921-926.
50. Vanura H, Ambrosch F, Berger RM et al. Study of pertussis vaccines in infants: Comparison of response to acellular pertussis DTP vaccines containing 25 μg of FHA and either 25 or 8 μg of PT with response to whole-cell pertussis DTP vaccine. Vaccine 1994; 12: 210-214.
51. Sandros J, Tuomanen E. Attachment factors of Bordetella pertussis: mimicry of eukaryotic cell recognition molecules. Trends in Microbiol 1993; 1: 192-195.
52. Bielik RJ, Patriarca PA, Mullen JR et al. Risk factors for community- and household-acquired pertussis during a large-scale outbreak in central Wisconsin. J. Infect Dis 1988; 175: 1134-1141.
53. Mortimer Jr EA. Pertussis and its prevention: a family affair. J Infect Dis 1990; 161: 473-479.
54. Novelli V, Al-Ansari H, Mok Q, Tasker R. Pertussis vaccination: is there a need for a booster dose? Lancet 1994; 344: 1225-1226.
55. Ruuskanen O, Noel A, Putto-Laurila A et al. Development of an acellular pertussis vaccine and its administration as a booster in healthy adults. Vaccine 1991; 9: 117-121.
56. Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response [see comments]. J Infect Dis 1990; 161: 487-492.
57. Oda M, Izumiya K, Sato Y, Hirayama M. Transplacental and transcolostral immunity to pertussis in a mouse model using acellular pertussis vaccine. J Infect Dis 1983; 148: 138-145.
58. Booy R, Aitken SJ, Taylor S et al. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age [see comments]. Lancet 1992; 339: 507-510.
59. Brownlie RM, Brahmbhatt HN, White DC et al. Stimulation of secretory antibodies against Bordetella pertussis antigens in the lungs of mice after oral or intranasal administration of liposome incorporated cell surface antigens. Microb Pathog 1993; 14: 149-160.
60. Cahill ES, O'Hagan DT, Illum L, Redhead K. Mice are protected against Bordetella pertussis infection by intra nasal immunization with filamentous haemagglutinin. FEMS Microbiol Lett 1993; 107: 211-216.
61. Guzman CA, Molinari G, Fountain MW, Rohde M. Timmis KN, Walker MJ. Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid. Infect Immun 1993; 61: 573-579.
62. Marwick C. Acellular pertussis vaccine hailed for infants. JAMA 1995: 274: 446-447.